ALR Technologies Announces Electronic Insulin Dosing Consultations by Endocrinologists; New Feature of Health-e-Connect Syste...
07 Maio 2014 - 9:18AM
Marketwired
ALR Technologies Announces Electronic Insulin Dosing Consultations
by Endocrinologists; New Feature of Health-e-Connect System Will
Encourage Widespread Adoption of Intensive Blood Glucose Management
RICHMOND, VA--(Marketwired - May 7, 2014) - ALR Technologies
(OTCBB: ALRT) announced that it has upgraded its Health-e-Connect
Diabetes Management System in order to facilitate online, insulin
dosing consultations for physicians. Through ALRT's
Health-e-Connect System, prescribing physicians will have the
option to receive an online second opinion on their recommended
insulin dose from an independent consulting endocrinologist.
The consulting endocrinologist will provide the dosing opinion
based on a review of actual blood glucose data from the patient's
meter in combination with other important factors necessary for
prescribing, such as current insulin dosage, height and weight.
ALRT's Health-e-Connect Diabetes Management System is an ideal tool
to assist providers with an online second opinion as patient blood
glucose data and other key information can be made available online
to the consulting specialist. Such a tool creates an easy method to
allow a prescribing clinician to regularly adjust a patient's
insulin dose without an office visit.
The Insulin Dose Adjustment Consultation (IDAC) system is in the
final testing phase with expected customer availability in
mid-June.
This new feature will provide many more physicians with the
capability to intensively manage the blood glucose of their
patients as ALRT's Diabetes Care Facilitators will monitor patient
blood glucose levels, helping to spot trends in the data that may
require a dose adjustment. As the number of patients with diabetes
is expected grow and the shortage of physicians accelerates,
providers will be able to care for more patients without
sacrificing the quality of care.
For patients, the regular adjustment of their insulin dose holds
the potential that their insulin dose may be optimized on a regular
basis, which may slow the progression of some comorbidities
associated with diabetes. Additionally, with the monitoring and
care facilitation embedded in the Health-e-Connect System, patients
may also find it easier to adhere to their insulin regimen.
Finally, for payers, the widespread adoption of intensive blood
glucose management would be a key tool in helping to manage the
escalating costs of diabetes care without the cost of additional
specialist office visits.
The proper dosing of insulin is one of the most important
challenges in the clinical practice of diabetes. Insulin doses that
are too low result in poor glucose control, leading to significant
microvascular complications and comorbidities. Insulin doses that
are too high can cause hypoglycemia, risking adverse events such as
unconsciousness, coma and even death. Besides these serious health
consequences for patients, the poor outcomes produced by improper
insulin dosing lead to significant, unnecessary healthcare
costs.
ALRT's CEO Sidney Chan said: "The clinical practice of diabetes
would be improved through a system that ensures patients are more
likely to be at their optimal dose of insulin. Intensive blood
glucose management has been shown to be effective and some patients
who are lucky enough to be treated by high-end endocrinologists
have access to its benefits. We want to bring this high level of
intensive treatment to primary care physicians and to a much
broader population of patients."
To view a video explaining this new tool, click here:
http://youtu.be/rRxEKUE4tkA
About ALR Technologies Inc.
ALR Technologies is a medical device company providing remote
monitoring and care facilitation for patients with chronic
diseases. ALRT has developed the FDA-cleared and HIPAA compliant
Health-e-Connect System that collects data from blood glucose
meters and uploads to a secure website. Trained Facilitators use
the System to affect efficiency of care among patients, clinicians
and caregivers to improve outcomes and assist health plans and
employers to meet their chronic disease management goals.
Currently, the Company is focused on diabetes and will expand its
services to cover other chronic diseases anchored on verifiable
data. More information about ALR Technologies, Inc. can be found at
www.alrt.com.
This release contains certain "forward-looking statements"
relating to ALR Technologies' business, and these statements
reflect the current views of ALR Technologies with respect to
future events and are subject to certain risks, uncertainties and
assumptions. When used, the words "estimate", "expect",
"anticipate", "believe" and similar expressions are intended to
identify such forward-looking statements. There are many factors
that could cause the actual results, performance or achievements of
ALR Technologies and its products to be materially different from
any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Further
management discussions of risks and uncertainties can be found in
the company's quarterly filings with the Securities Exchange.
Contact: Bill Smith: 203.762.1073 email:
bill.smith@alrt.com
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ALR Technologies (QB) (USOTC:ALRT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024